CYP2B6 Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port‐au‐Prince, Haiti by Leger, Paul et al.
CYP2B6 Variants and Plasma Efavirenz Concentrations during
Antiretroviral Therapy in Port-au-Prince, Haiti
Paul Leger, MD, MPH1, Rebecca Dillingham, MD, MPH2, Carole Anne Beauharnais, MD1,
Angela D. M. Kashuba, PharmD3, Naser L. Rezk, PhD3, Daniel W. Fitzgerald, MD1,4, Jean
William Pape, MD1,4, and David W. Haas, MD5,6
1Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO), Port-
au-Prince, Haiti
2Department of Medicine, Division of Infectious Disease and International Health and Public Health
Sciences, University of Virginia, Charlottesville, VA
3Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North
Carolina
4Department of Medicine, Weill Medical College of Cornell University, New York, NY
5Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
6Department of Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville,
Tennessee
Abstract
Background—Polymorphisms in CYP2B6 are known to predict increased steady-state plasma
concentrations of efavirenz. We characterized relationships between genetic polymorphisms and
plasma efavirenz concentrations among 45 Haitians who initiated antiretroviral therapy in Port-au-
Prince.
Methods—An observational study characterized relationships between clinical factors,
pharmacokinetics, and treatment response among antiretroviral-naïve patients initiating once-daily
efavirenz plus twice-daily AZT/3TC. Plasma drug concentrations were determined at weeks 2 and
4. Drug doses were directly observed by field workers or designated family members. We
retrospectively characterized relationships between efavirenz concentrations and 50 single
nucleotide polymorphisms in CYP2B6, and several polymorphisms in CYP2A6, CYP3A4, CYP3A5
and ABCB1.
Results—Plasma for efavirenz assay was obtained 13.9 ±1.6 hours (mean ± SD) post-dose. As
expected, CYP2B6 516G→T was associated with increased plasma efavirenz concentrations
(Spearman’s rho=0.71, P<0.0001), as were 10 polymorphisms in linkage disequilibrium with
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516G→T. Distinct CYP2B6 polymorphisms were associated with decreased plasma efavirenz
concentrations (greatest absolute rho=0.48, P=0.0008). Associations were replicated by results from
a recent pharmacokinetic study involving 34 healthy, HIV-negative African Americans.
Conclusions—Relatively frequent CYP2B6 polymorphisms may predict decreased plasma
efavirenz exposure in patients of African descent. If replicated in other cohorts, the implications of
these novel associations for treatment response warrant further study.
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INTRODUCTION
Initial therapy for HIV-1 infection with the non-nucleoside reverse transcriptase inhibitor
(NNRTI) efavirenz plus two nucleoside reverse transcriptase inhibitors (NRTIs) typically
provides sustained virologic and immunologic benefits, but some patients experience virologic
failure [1–6]. Efavirenz is metabolized primarily by cytochrome P450 (CYP) 2B6 [7]. A
frequent non-synonymous polymorphism in CYP2B6 exon 4 (516G→T, rs3745274) predicts
decreased plasma efavirenz clearance and increased plasma efavirenz exposure at steady state
[8–10], as does a less frequent non-synonymous CYP2B6 exon 9 polymorphism, 983T→C
(rs28399499) [11–13]. Increased frequencies of both CYP2B6 516T and 983C among
individuals of African ancestry [8–14] largely explain their greater mean plasma efavirenz
concentrations as compared to Caucasians [15–17]. Additional CYP2B6 polymorphisms have
been suggested to affect CYP2B6 activity [18], but have either been extremely infrequent or
have not predicted plasma efavirenz exposure in vivo. In two studies involving 169 and 489
individuals, respectively, and in which 15 non-synonymous exonic CYP2B6 polymorphisms
were assayed, only 516G→T and 983T→C appeared to predict substantial differences in
efavirenz exposure [12,13].
Most previous pharmacogenomics studies of efavirenz have focused on coding, non-
synonymous CYP2B6 polymorphisms [8,13]. However, many additional CYP2B6
polymorphisms in 5’ and 3’ untranslated regions (UTR) and introns could potentially affect
CYP2B6 expression or activity [19,20]. In this regard, a recent study explored associations
between 50 CYP2B6 polymorphisms and pharmacokinetics of single-dose efavirenz among 34
healthy, HIV-negative African Americans [21]. In addition to the expected pharmacokinetic
association with the so-called composite CYP2B6 516/983 genotype, associations were
suggested between an additional 13 CYP2B6 polymorphisms and efavirenz pharmacokinetics,
pending replication in other studies. These polymorphisms were frequent, were in non-coding
regions of CYP2B6, and some were not in strong linkage disequilibrium (LD) with either
CYP2B6 516G→T or 983T→C.
The present study was designed to characterize relationships between CYP2B6 polymorphisms
and steady-state plasma efavirenz concentrations among 45 HIV-positive, antiretroviral-naive
Haitians who initiated an efavirenz-containing regimen in Port-au-Prince. Our findings
replicate novel associations previously suggested between relatively frequent non-coding
CYP2B6 polymorphisms and interindividual variability in plasma efavirenz exposure, and
suggest that at least one CYP2B6 variant may be associated with an increased likelihood of
subtherapeutic plasma efavirenz concentrations.
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Study Subjects and Design
This pharmacogenomic study involved 45 Haitians of African descent. (An additional
individual with undetectable plasma efavirenz, AZT and 3TC concentrations was excluded
from analyses for presumed non-adherence). Eligible participants were HIV-1 seropositive,
had CD4+ T cells <200 cells/mm3, hemoglobin >7.5 mg/dL, and normal kidney and liver
function tests. Patients with prior antiretroviral exposure or requiring medications known or
predicted to interact with antiretrovirals were excluded. All participants initiated therapy with
efavirenz (600 mg every 24 hours in the evening) plus fixed-dose zidovudine/lamivudine
(AZT/3TC, 300/100 mg every 12 hours). To enhance medication adherence, during the four
weeks of therapy the study medications were administered under direct observation (morning
doses by study personnel [field workers] at the participant’s residence, evening doses by a
designated family member [accompagnateur].) All doses were documented in a medication
diary.
Plasma Drug Assays
Plasma samples for drug assays were obtained at week 2 and week 4 of therapy, before the
morning dose of AZT/3TC. Times since the prior doses of efavirenz, AZT and 3TC were
documented. Plasma was separated by centrifugation at 4°C and stored at −70°C. Efavirenz,
AZT and 3TC were quantified using two validated methods in the UNC Center for AIDS
Research Clinical Pharmacology and Analytical Chemistry Core [22,23]. The dynamic range
for efavirenz was 25 to 10,000 ng/mL, with intra- and interday precision of 4.8–5.5% and
accuracy of 100.4–101.7%. The dynamic range for AZT and 3TC was 10–10,000 ng/mL, with
intra- and interday precision of <7%, and accuracy of ≥90% for all concentrations.
Statistical Methods
Pharmacokinetic parameters are presented as median and interquartile ranges [IQR]. Body
mass index (BMI) was calculated as weight in kilograms divided by the square of the height
in meters. For each participant a single plasma efavirenz concentration value derived based on
the geometric mean of week 2 and week 4 values was used for statistical analyses. In one
individual without week 2 efavirenz data the week 4 value was used. The geometric mean
concentration value for each individual was then used to determine medians, interquartile
ranges, and correlations among groups of individuals. Spearman correlation coefficient (rho)
was used to assess for dose-response trends in bivariate relationships between continuous
variables and genotype, and to determine the directionality of such relationships. The same
analyses repeated using Jonckheere-Terpstra test for trend if three genotypes, or Wilcoxon rank
sum test if two genotypes, yielded remarkably similar P values (data not shown). For
CYP2B6 516/983, genotype was coded as an ordered continuous variable with 1 denoting
extensive, 2 intermediate, and 3 slow metabolizer. For other exploratory polymorphism
analyses, 1 denoted homozygous, 2 denoted heterozygous, and 3 denoted the other
homozygous genotype, ordered as A < C < G < T. (e.g. for 983T→C, C/C = 1, C/T = 2, T/T
= 3). For univariate correlations between plasma efavirenz concentrations and genetic
polymorphisms, P values that remained significant after Bonferroni correcting for multiple
tests are indicated in the Tables. All analyses used a 5% two-sided significance level and were
performed with STATA/IC version 10.0 (College Station, TX). Linkage disequilibrium plots
(LD) and values r2 were generated using Haploview [24]. Estimated haplotypes for each
individual were generated using Powermarker [25], excluding two individuals with less than
85% haplotype probability. Hardy-Weinberg equilibrium was assessed using exact tests [26].
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Characterization of Human Genetic Variants
Genomic DNA was extracted from saliva collected with Oragene kits (DNA Genotek Inc,
Ottawa, Ontario, Canada). A total of 56 single nucleotide polymorphisms (50 in CYP2B6, 1
in CYP2A6, 1 in CYP3A4, 1 in CYP3A5, and 3 in ABCB1) were assayed in the Vanderbilt DNA
Resources Core using MassARRAY® iPLEX Gold (Sequenom, Inc.). Our strategy for
CYP2B6 Sequenom assay design was a follows. We tagged the entire CYP2B6 gene using
SeattleSNPs [20], including 5 kB in each 5’ and 3’ untranslated regions (UTR), using a
cosmopolitan strategy across populations (Yoruba, Asian, African-American, European-
American, and Hispanic) with a 5% allelic frequency cut-off, a 0.80 threshold for r2, 85% data
convergence for tagging polymorphisms, and 70% data convergence for clustering. Additional
polymorphisms of interest (but that were not extremely infrequent) were added based on
previous reports [12,13]. We also added polymorphisms with at least 5% allelic frequency in
20 kB of the 5’ UTR identified using Ensembl Genome Browser [27], as well as upstream
polymorphisms possibly associated with CYP2B6 expression based on a previous report
[28]. (Final Sequenom assay design available upon request.) Genotypes were confirmed by
visual inspection of plots. Laboratory personnel with no knowledge of clinical data performed
genotyping. All assays were run in duplicate, and were in complete agreement.
Composite CYP2B6 516/983 genotypes, based on reported associations between CYP2B6
516G→T and 983T→C and steady-state efavirenz pharmacokinetics [11–13], were assigned
as described elsewhere [21]: Extensive metabolizer, no variant allele at either position 516 or
983; intermediate metabolizer, a single variant allele at either position 516 or 983, but not both;
slow metabolizer, two variant alleles (i.e. either 516 T/T, 983 C/C, or 516 G/T with 983 T/C).
Relative CYP2B6 gene copy number was assessed by allelotyping at 17 polymorphic sites
using the Sequenom platform.
Protection of Human Subjects
Study volunteers were enrolled and followed at the GHESKIO CENTERS clinic in Port-au-
Prince, Haiti. Human experimentation guidelines of the US Department of Health and Human
Services were followed in the conduct of this research. All work was conducted in accordance
with the Declaration of Helsinki. The study was approved by the Institutional Review Board
of GHESKIO, Cornell University, University of Virginia, and Vanderbilt University, and all
participants provided written informed consent.
RESULTS
Participant Characteristics
Forty-five Haitians of African descent were included in this pharmacogenomic association
study. Median baseline age was 36 years [IQR 32 – 43 years], median weight was 56 kg [IQR
48 – 59 kg], median BMI was 20.8 kg/m2 [IQR 19.0 – 22.9 kg/m2] and 27 (60%) were female.
At baseline, median plasma HIV-1 RNA was 5.3 log10 copies/mL [IQR 4.9 – 5.6 log10 copies/
mL] and CD4+ T cell count was 54 cells/mm3 [IQR 25 – 138 cells/mm3].
Efavirenz plasma concentrations
The 45 participants initiated three-drug therapy with efavirenz, AZT and 3TC. Plasma for
efavirenz assay at week 2 was obtained 14.1 ± 1.8 hours (mean ± S.D.) post-dose, and at week
4 was obtained 13.8 ± 1.4 hours post-dose. Intraindividual differences between week 2 and
week 4 efavirenz concentration values were 18.6% ± 15.5% (mean ± SD). One individual had
extremely low plasma efavirenz concentration of 241 ng/mL and 126 ng/mL. Paired efavirenz
concentration values were used to calculate geometric mean concentrations for each individual
(used in all analyses hereafter). There was an approximately 100-fold interindividual range in
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plasma efavirenz concentrations. The median plasma efavirenz concentration was 3,295 ng/
mL (IQR 2,435 – 6,473 ng/mL, range 174 – 15,380 ng/mL). There was no apparent association
between either BMI or sex and plasma efavirenz concentrations (P > 0.05 for each comparison).
Genetic polymorphisms
Minor allele frequencies for all 56 polymorphisms are presented in Supplemental Table. All
were in Hardy-Weinberg equilibrium (P > 0.05). Based on composite CYP2B6 516/983
genotype (as defined in Materials and Methods), 10 individuals were predicted to be slow
metabolizers, 21 intermediate metabolizers, and 14 extensive metabolizers. An LD plot for
CYP2B6 polymorphisms is provided in Figure 1.
Genetic predictors of plasma efavirenz concentrations
Of the 56 polymorphisms assayed, 20 were associated with efavirenz plasma concentrations
at rho > 0.3 or < −0.3 (without correcting for multiple comparisons) as shown in Table 1.
Associations for all 56 polymorphisms are provided in Supplemental Table and Supplemental
Figure. There was, as expected, a strong correlation between composite CYP2B6 516/983
genotype and higher plasma efavirenz concentrations (rho=0.76, P < 0.0001, Figure 2A). In
analyses involving CYP2B6 516G→T and 983T→C separately there was also a significant
association between CYP2B6 516G→T and efavirenz plasma concentrations (rho= 0.72, P <
0.0001). Of the other 19 polymorphisms associated with plasma efavirenz concentrations, 10
were in LD with CYP2B6 516G→T at r2 > 0.5 (Figure 1 and Table 1). These included 3 5’
UTR, 6 intronic and 1 exonic polymorphisms. Based on rho values, no polymorphism was
more strongly associated with plasma efavirenz concentrations than CYP2B6 516G→T.
Among 10 individuals with slow metabolizer composite CYP2B6 516/983 genotypes, plasma
efavirenz concentrations did not differ in 2 individuals heterozygous for the CYP2A6 promoter
polymorphism (rs28399433) as compared to the 8 individuals lacking this polymorphism (data
not shown).
Nine polymorphisms that were not in strong LD with CYP2B6 516G→T (r2 < 0.5) were also
associated with plasma efavirenz concentrations at rho > 0.3 or < −0.3 (Figure 1 and Table 1).
These included 3 5’ UTR and 5 intronic polymorphisms in CYP2B6, and the CYP2A6 promoter
polymorphism. Of these 9 polymorphisms, an intron 8 polymorphism (rs36118214) was most
strongly associated with plasma efavirenz concentrations (rho = 0.48, P = 0.0008, Figure 2B).
In contrast to both CYP2B6 516G→T and 983T→C, the less frequent rs36118214 A allele
appeared to predict lower plasma efavirenz concentrations. Two of the other polymorphisms
associated with plasma efavirenz concentrations were in LD with rs36118214 at r2 > 0.5
(rs1872121 at r2 = 0.941, rs12721649 at r2 = 0.668, Figure 2C and 2D).
To assess whether associations were spurious, we compared rho values from the present study
with those from a recent study which characterized genetic variants and plasma efavirenz
pharmacokinetics among 34 healthy, HIV-negative African Americans who received a single
200-mg dose of nevirapine, followed several weeks later by a single 600-mg dose of efavirenz
[21]. Forty nine polymorphisms assayed in the present study were also in the previous study.
Three polymorphisms associated with plasma efavirenz concentrations in the present study
(rs28399433, rs8109818, and rs10853744) were not assayed in the previous study.
Associations replicated remarkably well between studies, including polymorphisms in LD with
CYP2B6 516G→T, and those in LD with rs36118214 (Figure 3). This supports the validity of
these associations.
As shown in Figure 2B, four individuals were homozygous for rs36118214, of whom one had
extremely low plasma efavirenz concentrations (241 ng/mL and 126 ng/mL at weeks 2 and 4,
respectively). This individual was also homozygous for rs1872121 and heterozygous for
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rs12721649. To further assess associations with lower plasma efavirenz concentrations,
subgroup analyses were performed on the 14 individuals with extensive metabolizer composite
516/983 genotypes. In this subgroup analysis, of the 20 polymorphisms associated with plasma
efavirenz concentrations noted above only rs36118214 (Figure 2E) and rs1872121 (not shown)
were significantly associated with plasma efavirenz concentrations (rho = 0.774, P = 0.0012
and rho = 0.601, P = 0.023, respectively). In sensitivity analyses which excluded the one
individual with very low plasma efavirenz concentrations, the association with rs36118214
persisted in the remaining 13 individuals (rho = 0.7325, P = 0.0044), whereas the association
with rs1872121 did not (rho = 0.5258, P = 0.0649). Although clinical relevance is uncertain
with so few individuals, the patient in the present study with extremely low plasma efavirenz
concentrations experienced virologic failure at week 24. No study participant discontinued
efavirenz because of medication side effects.
In the previous study of 34 HIV-negative African Americans [21], the only individual
homozygous for rs36118214 was also the only individual with extremely rapid plasma
clearance of efavirenz. That individual had a 24-hour efavirenz concentration of 89 ng/mL,
considerably less than the median value of 582 ng/mL among other participants, and was
heterozygous for rs1872121 and homozygous for rs12721649. The association with
rs36118214 in that study was also apparent in the subgroup of 10 individuals with extensive
metabolizer composite 516/983 genotype (rho = 0.844, P = 0.0021, Figure 2F), and in
sensitivity analyses which excluded the individual with extremely low plasma efavirenz
concentrations (n = 9, rho = 0.782, P = 0.0076).
To further describe relationships between rs36118214 and plasma efavirenz concentrations
estimated haplotypes were generated which span 14 polymorphisms from CYP2B6 516G→T
to rs10853744. This encompasses two adjacent LD blocks (Figure 1) and includes rs36118214,
rs12721649, and 983T→C. The 14 predicted haplotypes (numbered based on frequency, not
based on “star” nomenclature [18]) and relationships between diplotypes and plasma efavirenz
concentrations are shown in Figure 4. Diplotypes with at least one rs36118214 A allele
(haplotypes 2, 6 and 10) but no slow metabolizer allele (haplotypes 1, 9 and 14) were associated
with lower plasma efavirenz concentrations. In contrast, diplotypes with at least one slow
metabolizer allele at position 516G→T or 983T→C were associated with higher plasma
efavirenz concentrations regardless of whether an rs36118214 A allele was present. Of the 4
individuals homozygous for rs36118214, two were haplotype 2/10 (including the individual
with very low plasma efavirenz concentrations) and two were haplotype 2/6. Thus, no
haplotype was unique to the individual with very low efavirenz concentrations.
Lower plasma efavirenz concentrations could be a consequence of increased CYP2B6 gene
copy number. By allelotyping at 17 single nucleotide polymorphisms across CYP2B6, 37
participants (including the individual with very low plasma efavirenz concentrations) could be
studied for gene copy number by allelotyping. None had more than two copies of CYP2B6
(data not shown).
Although the present study included a directly observed strategy to enhance adherence, and
medication diaries documented complete adherence at weeks 2 and 4, we cannot exclude
nonadherence. (In fact, one individual with no detectable efavirenz, AZT or 3TC in plasma
was excluded from analyses for presumed non-adherence, despite medication diaries indicating
adherence). If nonadherence covaried with genotype, one might expect this to also affect AZT
and 3TC. However, there was no correlation between plasma concentrations of efavirenz and
either AZT or 3TC (rho = 0.0187, P = 0.9 and rho = −0.0057, P = 0.97, respectively), and there
was no association between any of the 56 polymorphisms and plasma concentrations of either
AZT or 3TC (data not shown). This suggests that associations between polymorphisms and
efavirenz concentrations were not explained by gross differences in adherence.
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Efavirenz is a preferred component of first-line regimens for HIV-1 infection [1,2], based on
its superior performance in randomized clinical trials [3–6]. It is one of the most widely
prescribed antiretroviral drugs in both affluent and resource-limited countries. The most
important finding from the present study is that at least one CYP2B6 genetic polymorphism
appears to be associated with decreased plasma efavirenz exposure. Replication of associations
between the present study, involving HIV-infected Haitians who initiated antiretroviral therapy
in Port-au-Prince, and a previous study involving healthy African Americans in Nashville,
Tennessee [21], support the validity of this finding. This does not, however, preclude the need
for further replication in larger cohorts.
Many genetic polymorphisms vary in frequency among populations [29]. The polymorphism
most consistently associated with lower plasma efavirenz concentrations in the present report,
rs36118214, was relatively frequent in both this study and in the previous study (minor allele
frequency 0.24 and 0.22, respectively)[21]. This polymorphism appears to vary markedly in
frequency depending on geographic region of ancestry. According to the NCBI web-based
resource, dbSNP [14], the frequency of the A allele (based on relatively few genotypes) was
0.42 among Sub-Saharan Africans and 0.21 among African American, but was absent among
Europeans and Asians. Genetic polymorphisms that differ in frequency among populations
might help explain, at least in part, disparate responses to therapy. In this regard it is noteworthy
that in AIDS Clinical Trials Group protocol A5095, in which most participants received
efavirenz-containing regimens, virologic failure was considerably more frequent among blacks
than among whites, particularly in analyses that adjusted for self-reported nonadherence [30,
31].
Efavirenz is primarily metabolized by CYP2B6 [7]. A number of previous studies have
examined associations between genetic polymorphisms and efavirenz pharmacokinetics and/
or treatment response [8–13,32]. Associations between increased plasma efavirenz exposure,
CYP2B6 516G→T [8–13], and 983T→C [11–13] have been consistent across multiple studies
and populations. Although the 516G→T polymorphism alters amino acid sequence, its effect
appears to be through aberrant splicing which reduces functional mRNA and protein [33].
Additional CYP2B6 polymorphisms have been suggested to affect CYP2B6 activity [18], but
are either extremely infrequent or have not predicted plasma efavirenz exposure in vivo [12,
13]. In analyses designed to identify CYP2B6 copy number variants among 226 individuals,
including 138 whites and 77 blacks, only one individual heterozygous for a copy number
variant was identified [34]. This was a crossover between CYP2B6 and the pseudogene
CYP2B7 which was associated with increased plasma efavirenz concentrations. CYP2A6,
which is located approximately 141 kilobases upstream of CYP2B6 on chromosome 19,
catalyzes a secondary metabolism pathway for efavirenz. A recent study suggests that loss of
function polymorphisms in CYP2A6 (including the promoter polymorphism studied herein)
when combined with CYP2B6 slow metabolism genotypes may predict particularly high
efavirenz concentrations [35]. Our inability to show this association with a CYP2A6 promoter
polymorphism (rs28399433) among composite 516/983 slow metabolizers may reflect the
absence of individuals homozygous for the G allele.
The mechanism(s) by which the polymorphisms identified herein would be associated with
decreased efavirenz exposure are unknown. We found no evidence of increased CYP2B6 copy
number. Furthermore, the three implicated CYP2B6 polymorphisms are non-coding
(rs36118214 and rs12721649 in intron 8, rs1872121 in intron 3). There are several possibilities.
These polymorphisms may tag as yet unidentified chromosome 19 variants that are directly
causative. Alternatively, at least one of these polymorphisms may in some way be involved in
regulating CYP2B6 transcription. Or these may cause aberrant splicing of CYP2B6 that in some
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way increases enzymatic activity. Extensive genotyping of large cohorts may identify more
precise genetic predictors of low plasma efavirenz concentrations.
There were limitations to the present study. Because the sample size was relatively small, only
four individuals were homozygous for the polymorphism most strongly associated with
decreased plasma efavirenz concentrations. Larger cohorts would also strengthen haplotype
analyses. Despite associations being consistent between two studies [21], genomic association
studies are plagued by false discovery [36]. It is therefore critical that these putative predictors
of decreased plasma efavirenz exposure be replicated in other cohorts. In addition, because
genetic predictors of efavirenz pharmacokinetics may differ depending on geographic region
of ancestry, associations may differ in other populations. Associations with virologic response
in large cohorts should be assessed to understand potential implications for clinical care.
Despite the use of directly observed drug administration to enhance adherence, we cannot
absolutely exclude nonadherence. We used self-identified race rather than population-
informative genetic markers, which could identify unrecognized population stratification.
These findings, if replicated in additional cohorts, may have implications for the HIV-1
pandemic. A lower therapeutic cut-off of 1,000 ng/mL has been suggested for efavirenz [37].
Virologic failure with efavirenz plus two NRTIs typically leads to emergence of resistance to
NNRTIs and NRTIs [38]. With continued selective pressure, progressive cross-resistance to
multiple drugs including newer NNTRIs such as etravirine can develop [39]. This may result
in HIV-1 disease progression, fewer future treatment options, and transmission of multidrug-
resistant virus to others. Antiretroviral prescribing strategies could be improved by
understanding whether certain individuals are genetically predisposed to virologic failure with
efavirenz.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Linkage disequilibrium (LD) plot of CYP2B6 polymorphisms. Data from the 45 participants
are included. Black, r2 = 1; shades of grey 0 < r2 < 1; white, r2 = 0. The plot was generated
using Haploview [24]. Solid arrows indicate the CYP2B6 516G→T (rs3745274)
polymorphism. Open arrows indicate rs36118214. The CYP2A6 promoter polymorphism
(rs28399433) is also included at far left. Four LD blocks are shown.
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Relationships between selected polymorphisms and plasma efavirenz concentrations. Panel
A: Relationship between composite CYP2B6 516/983 genotype and plasma efavirenz
concentrations among all study participants. Panel B: Relationship between rs36118214 and
plasma efavirenz concentrations among all study participants. Panel C: Relationship between
rs1872121 and plasma efavirenz concentrations among all study participants. Panel D:
Relationship between rs12721649 and plasma efavirenz concentrations among all study
participants. Panel E: Relationship between rs36118214 and plasma efavirenz concentrations
among 14 participants with composite CYP2B6 516/983 extensive metabolizer genotypes.
Panel F: From a previous study in which 34 healthy, HIV-negative African Americans received
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a single 600 mg dose of efavirenz [21], relationship between rs36118214 and plasma efavirenz
concentrations 24 hours post-dose among 10 participants with composite CYP2B6 516/983
extensive metabolizer genotypes. Horizontal lines represent medians. Each marker in panels
A through E represents the geometric mean of paired efavirenz concentrations from each
participant.
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Relationships between Spearman’s rho values for each polymorphism from the present and
previous studies. Open triangles indentify polymorphisms in LD with CYP2B6 516G→T
(rs3745274) at r2 > 0.5. Closed circles identify polymorphisms in LD with rs36118214 at r2 >
0.5. Open circles identify other polymorphisms. The previous study characterized associations
between polymorphisms and efavirenz pharmacokinetic following a single 600-mg dose of
efavirenz among 34 healthy, HIV-negative African Americans [21]. From that study rho values
for 24-hour post-dose efavirenz concentrations are shown. Dashed lines bound rho values >
0.3 or < −0.3. The sign (+ or −) of the rho value signifies ordering of genotypes bases (A < C
< G < T) as explained in Materials and Methods, not whether the minor allele predicts higher
or lower plasma efavirenz concentrations.
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Relationships between CYP2B6 diplotypes and plasma efavirenz concentrations. Panel A:
Estimated haplotypes in region spanning CYP2B6 rs3745274 (516G→T) to rs36118214.
Haplotypes are numbered from 1 to 14 in order of decreasing frequency. Shaded positions
represent minor alleles for rs3745274 (516G→T), rs28399499 (983T→C), and rs36118214.
Estimated haplotypes were generated using Powermarker [25] for the region spanning
rs3745274 to rs36118214. Panel B: Relationships between CYP2B6 diplotypes and plasma
efavirenz concentrations. Horizontal lines represent medians. Diplotypes are ordered from
lowest to highest median efavirenz concentrations. Each marker represents the geometric mean
of paired efavirenz concentrations from each participant.
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